Formycon AG Announces Non-Cash Impairments and Revises Adjusted EBITDA Guidance

Formycon AG recorded non-cash impairments of €39 million for FYB201 and €82 million for FYB202, citing increased competition and price pressure. It cut its FY2026 adjusted EBITDA guidance to a loss of €15 million to €5 million, from its prior forecast of €5 million to €15 million. Revenue guidance remains €60–70 million, EBITDA guidance €0–10 million, and year-end net working capital guidance €20–30 million. Management plans to discuss the developments on a conference call scheduled for November 12, 2026.